LUN and HLUN-A Related Headlines
Go Back- Lundbeck announces headline results from Phase IV THRIVE trial evaluating VYEPTI® (eptinezumab) following inadequate response to prior CGRP-targeting preventive therapy
- Lundbeck announces last patient randomized in DEEp SEA, a Phase III trial of bexicaserin in Dravet syndrome
- Strong growth from Vyepti® and focused commercial execution drive total revenue growth of +16% CER (+13% CER underlying) in H1 2026
- Lundbeckfond Invest A/S launches voluntary exchange offer for A-shares in H. Lundbeck A/S
- FDA grants Lundbeck Fast Track status for narcolepsy drug candidate
- Lundbeck receives FDA Fast Track designation for Lu AH69593, an investigational orexin 2 receptor agonist for narcolepsy
- Lundbeck announces last patient randomized in DEEp OCEAN, a large Phase III trial in developmental and epileptic encephalopathies (DEEs)
- Tarek Samad appointed EVP, Head of Research & Development at Lundbeck
- Lundbeck presents new Phase II asedebart data in Cushing's disease at ENDO 2026
- Lundbeck to showcase new neurology data at the American Academy of Neurology Annual Meeting
- Lundbeck appoints Markus Kede SVP & Chief AI Officer
- Lundbeck appoints Chief AI Officer
- Lundbeck presents new real-world data highlighting meaningful improvements in patients severely impacted by migraine initiating Vyepti® (eptinezumab), at HCOP Annual Conference
LUN and HLUN-A Related Press Releases
Go Back- Lundbeck announces headline results from Phase IV THRIVE trial evaluating VYEPTI® (eptinezumab) following inadequate response to prior CGRP-targeting preventive therapy
- Lundbeck announces last patient randomized in DEEp SEA, a Phase III trial of bexicaserin in Dravet syndrome
- Strong growth from Vyepti® and focused commercial execution drive total revenue growth of +16% CER (+13% CER underlying) in H1 2026
- Lundbeckfond Invest A/S launches voluntary exchange offer for A-shares in H. Lundbeck A/S
- Lundbeck receives FDA Fast Track designation for Lu AH69593, an investigational orexin 2 receptor agonist for narcolepsy
- Lundbeck announces last patient randomized in DEEp OCEAN, a large Phase III trial in developmental and epileptic encephalopathies (DEEs)
- Tarek Samad appointed EVP, Head of Research & Development at Lundbeck
- Lundbeck presents new Phase II asedebart data in Cushing's disease at ENDO 2026
- Lundbeck to showcase new neurology data at the American Academy of Neurology Annual Meeting
- Lundbeck appoints Chief AI Officer
- Lundbeck presents new real-world data highlighting meaningful improvements in patients severely impacted by migraine initiating Vyepti® (eptinezumab), at HCOP Annual Conference
